Peisah Carmelle, Strukovski Julie-Anne, Wijeratne Chanaka, Mulholland Rosalind, Luscombe Georgina, Brodaty Henry
Specialist Mental Health Services for Older People,Mental Health Drug and Alcohol,Northern Sydney Local Health District,Sydney,Australia.
University of NSW,Sydney,Australia.
Int Psychogeriatr. 2015 Aug;27(8):1313-22. doi: 10.1017/S1041610214002816. Epub 2015 Feb 2.
Behavioral and psychological symptoms of dementia (BPSD) are virtually ubiquitous in dementia. Excessive recourse to use of psychotropics which have high risk to benefit ratio remains a global problem. We aimed to identify components of quality prescribing in BPSD to develop a tool for quality prescribing and to test this tool.
We used Delphi methodology to identify elements of quality prescribing in BPSD. The tool was tested by a range of medical and nursing professionals on 48 patients, in inpatient and ambulatory settings in Northern Sydney Local Health District, Australia.
Consensual opinion using Delphi method was that quality prescribing in dementia comprised ten factors including failure to use first line non-pharmacological strategies, indication, choice of drug, consent, dosage, mode of administration, titration, polypharmacy, toxicity, and review. These elements formed the quality use of medications in dementia (QUM-D) tool, lower scores of which reflected quality prescribing, with a possible range of scores from 0 to 30. When inter-rater reliability was tested on a subgroup of raters, QUM-D showed high inter-rater reliability. A significant reduction in QUM-D scores was demonstrated from baseline to follow-up, mean difference being 5.3 (SD = 3.8; 95% confidence interval 4.1-6.4; t = 9.5; df = 47; p < 0.001). There was also a significant reduction in score from baseline to follow-up when rated by clinical nurse consultants from a specialized behavior assessment management service (BAMS) (N = 12).
The QUM-D is a tool which may help to improve quality prescribing practices in the context of BPSD. In this setting, we consider quality prescribing, and accordingly the obligations of prescribers, to be an inclusive concept rather than just adding to the mantra of "not prescribing."
痴呆的行为和心理症状(BPSD)在痴呆患者中几乎普遍存在。过度依赖使用效益风险比高的精神药物仍然是一个全球性问题。我们旨在确定BPSD中优质处方的组成部分,以开发一种优质处方工具并对其进行测试。
我们采用德尔菲法来确定BPSD中优质处方的要素。该工具由一系列医学和护理专业人员在澳大利亚悉尼北部地方卫生区的住院和门诊环境中,对48名患者进行了测试。
使用德尔菲法达成的共识意见是,痴呆的优质处方包括十个因素,即未使用一线非药物策略、适应症、药物选择、同意、剂量、给药方式、滴定、联合用药、毒性和复查。这些要素构成了痴呆患者药物优质使用(QUM-D)工具,其得分越低反映处方质量越高,得分范围可能为0至30分。当对一部分评分者进行评分者间信度测试时,QUM-D显示出较高的评分者间信度。从基线到随访,QUM-D得分显著降低,平均差异为5.3(标准差=3.8;95%置信区间4.1-6.4;t=9.5;自由度=47;p<0.001)。由专门的行为评估管理服务(BAMS)的临床护士顾问进行评分时,从基线到随访得分也显著降低(N=12)。
QUM-D是一种有助于在BPSD背景下改善优质处方实践的工具。在这种情况下,我们认为优质处方以及相应的开处方者的义务是一个包容性概念,而不仅仅是增加“不开处方”的口头禅。